Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCoherus BioSciences Inc

Coherus BioSciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.6409 USD 0.00(0%)
Last update at 2026-11-10T21:00:00Z
VOLUME
4729370
Market Cap
205.49M

Momentum Score

…

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.60
Low
0.80
High
52 Week Price Range
1.09
Low
2.62
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Coherus BioSciences is a commercial-stage biotechnology company developing and commercializing biologic therapies with a focus on immuno-oncology and biosimilar supportive-care products. Long-term growth may be driven by sales of approved biologics, clinical progress in its pipeline, and partnerships that could expand market access, which may make it attractive to investors seeking exposure to biologics and biosimilars.

Material risks include clinical and regulatory setbacks, strong competition from larger biologics players, patent litigation risk and potential need for additional funding if revenue underperforms.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.64
Dividend Yield
-
Revenue TTM
50.94M
Revenue Per Share
0.39
Gross Profit TTM
35.12M
Debt / Equity
0.66
ROE
-178.39%
Net Debt
-48.54M
ROCE
-149.50%
Diluted EPS TTM
-1.16

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -183.12M 28.51M -238.27M -291.75M -287.10M
Net income -170.29M 28.51M -237.89M -326.63M -306.32M
Selling general administrative 100.60M 139.54M 192.01M 187.98M 161.01M
Selling and marketing expenses - 10.90M - 10.50M 8.70M
Gross profit 24.43M 149.41M 94.46M 140.96M 268.96M
Reconciled depreciation 3.92M 5.28M 3.79M 3.70M 3.45M
Ebit -174.12M 55.66M -197.73M -259.28M -266.35M
Ebitda -170.20M 60.94M -193.94M -255.58M -260.69M
Depreciation and amortization 3.92M 5.28M 3.79M 3.70M 5.66M
Non operating income net other - - - -2.40M -0.28M
Operating income -179.53M -111.67M -203.20M -256.88M -263.86M
Other operating expenses 221.71M 378.63M 460.44M 467.92M 590.41M
Interest expense 9.00M 27.16M 40.54M 32.47M 22.96M
Tax provision 0.00M 0.00M -0.38M 0.00M 1.05M
Net interest income -9.00M -27.16M -40.54M -32.47M -22.96M
Income tax expense -332.81M 28.51M -0.38M 34.87M 19.22M
Total revenue 42.17M 266.96M 257.24M 211.04M 326.55M
Total operating expenses 203.97M 261.07M 301.45M 397.84M 532.82M
Cost of revenue 17.74M 117.55M 162.78M 70.08M 57.59M
Total other income expense net -3.59M 140.17M -35.07M -34.87M -23.24M
Net income from continuing ops -183.12M 28.51M -237.89M -291.75M -287.10M
Net income applicable to common shares - - - -291.75M -287.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 258.34M 448.53M 629.60M 480.85M 679.33M
Intangible assets 46.24M 53.65M 70.73M 5.93M 2.62M
Other current assets 12.99M 23.17M 34.76M 22.92M 24.46M
Total liab 197.33M 580.52M 823.03M 618.26M 581.61M
Total stockholder equity 61.01M -131.99M -193.43M -137.42M 97.73M
Other current liab 130.13M 252.83M 294.41M 38.62M 59.38M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1382.97M -1550.99M -1579.50M -1341.61M -1049.85M
Other liab - - - 3.47M 94.30M
Good will - 0.00M 0.94M - 0.94M
Other assets 18.99M - - 64.15M 45.87M
Cash 88.88M 125.99M 102.89M 63.55M 417.19M
Total current liabilities 141.88M 282.98M 331.77M 54.46M 79.03M
Net debt -48.54M 143.92M 377.95M 407.51M -8.91M
Short term debt 1.83M 1.69M 2.15M 4.32M 3.49M
Short long term debt total 40.34M 269.90M 480.84M 471.06M 408.28M
Other stockholder equity 1444.17M 1419.27M 1386.31M 1204.43M 1147.84M
Property plant equipment - - - 85.01M 63.42M
Total current assets 206.71M 341.58M 475.63M 416.70M 633.47M
Net tangible assets - - - -143.35M 97.73M
Short term investments 83.25M 0.00M 14.86M 128.13M -
Net receivables 18.42M 122.33M 260.52M 109.96M 123.02M
Long term debt 37.05M 264.93M 473.37M 225.57M 408.28M
Inventory 3.17M 70.09M 62.60M 115.05M 93.25M
Accounts payable 9.91M 28.46M 35.22M 11.53M 16.16M
Accumulated other comprehensive income -0.20M -0.28M -0.25M -0.25M -0.27M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -1341.61M -1049.85M
Non currrent assets other 4.05M 50.47M 70.82M 49.47M 34.49M
Non current assets total 51.64M 106.95M 153.97M 64.15M 45.87M
Capital lease obligations 3.29M 4.98M 7.47M 9.36M 10.74M
Long term debt total - - - 225.57M 381.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -82.38M 230.32M 144.64M -127.38M -1.12M
Change to liabilities - - - -2.76M 18.58M
Total cashflows from investing activities 375.09M 230.32M - -166.85M -138.41M
Net borrowings -280.84M -223.41M - 49.93M -0.67M
Total cash from financing activities -273.70M -186.97M 69.60M 54.33M 51.88M
Change to operating activities - - - -40.41M 13.68M
Net income 168.02M 28.51M -237.89M -291.75M -287.10M
Change in cash -37.13M 22.91M 39.36M -353.65M -123.96M
Begin period cash flow 126.25M 103.34M 63.99M 417.63M 541.60M
End period cash flow 89.12M 126.25M 103.34M 63.99M 417.63M
Total cash from operating activities -138.51M -20.44M -174.88M -241.12M -37.43M
Issuance of capital stock 7.89M 1.46M 71.72M 6.36M 40.90M
Depreciation 3.92M 5.28M 3.79M 3.70M 3.45M
Other cashflows from investing activities 457.46M 215.43M - -37.43M -1.29M
Dividends paid - - - 3.74M 1.75M
Change to inventory -17.11M -31.95M -46.73M -47.35M -6.25M
Change to account receivables 93.56M 149.35M -150.68M 13.05M 34.06M
Sale purchase of stock - - -3.59M -3.74M -1.75M
Other cashflows from financing activities -48.77M 34.98M -2.12M -1.96M 10.98M
Change to netincome - - - 82.96M 249.67M
Capital expenditures 0.00M 0.00M 0.29M 2.04M 1.29M
Change receivables - - - 13.05M 34.06M
Cash flows other operating - - - -5.41M 134.77M
Cash and cash equivalents changes - - - -353.65M -123.96M
Change in working capital -5.84M 55.89M -36.83M -79.26M 42.36M
Stock based compensation 16.97M 27.80M 43.11M 50.74M 51.36M
Other non cash items -321.58M -137.92M 52.93M 75.45M 143.05M
Free cash flow -138.51M -20.44M -175.17M -243.16M -38.72M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CHRS
Coherus BioSciences Inc		 -
-%		 0.64 - 41.15 4.03 3.62 3.03 3.54
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Coherus BioSciences Inc

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

333 Twin Dolphin Drive, Redwood City, CA, United States, 94065

650 649 3530

https://www.coherus.com

144

Name Title Year Born
Mr. Dennis M. Lanfear Chairman, Pres & CEO 1955
Mr. McDavid Stilwell Chief Financial Officer 1972
Mr. Vladimir Vexler Ph.D. Chief Scientific Officer 1958
Mr. Bryan J. Mcmichael Sr. VP of Accounting, Principal Accounting Officer & Corp. Controller 1978
Mr. Richard L. Hameister Chief Technical Officer NA
Mr. Christopher W. Slavinsky Chief Bus. & Legal Officer 1973
Cheston Turbyfill VP of Communications NA
Ms. Karen Kotz Exec. VP of Sales & Strategic Accounts NA
Ms. Rebecca Sunshine Chief HR Officer 1963
Mr. Michael Chen Sr. VP of Commercial Analytics & Trade NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…